Reversible Ocular Toxicity of Oxaliplatin: A Case Report.
ocular toxicity
oxaliplatin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
12
7
2019
Statut:
epublish
Résumé
Oxaliplatin, a platinum-based chemotherapy agent, is commonly used in the treatment of various malignancies. Common adverse effects involve neurological, hematological, gastrointestinal system, and hypersensitivity, and rarely ocular changes have also been reported. We describe the case of a 71-year-old male, who developed reversible ocular toxicity after receiving oxaliplatin for treatment for pancreatic cancer.
Identifiants
pubmed: 31293842
doi: 10.7759/cureus.4582
pmc: PMC6605969
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e4582Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Drugs. 2003;63(19):2127-56
pubmed: 12962525
Ann Oncol. 2004 Mar;15(3):460-6
pubmed: 14998849
Clin Ther. 2017 Nov;39(11):2125-2134
pubmed: 28939405
Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46
pubmed: 15871765
Case Rep Oncol. 2010 Nov 22;3(3):423-427
pubmed: 21151636
Brain. 2009 Oct;132(Pt 10):2712-23
pubmed: 19745023
Clin J Oncol Nurs. 2005 Feb;9(1):31-44
pubmed: 15751497
Br J Cancer. 2003 Aug 4;89(3):477-81
pubmed: 12888815
BMC Cancer. 2005 Sep 16;5:116
pubmed: 16168057
Expert Opin Pharmacother. 2004 Oct;5(10):2159-70
pubmed: 15461551
Clin J Oncol Nurs. 2006 Apr;10(2):227-9
pubmed: 16708705
Gan To Kagaku Ryoho. 2015 Nov;42(11):1401-5
pubmed: 26602399
Surv Ophthalmol. 1989 Nov-Dec;34(3):209-30
pubmed: 2694416